Risk of drug interactions among children accessing drugs through health Canada's Special Access Programme

Canadian Journal of Hospital Pharmacy

Volumn 60, Issue 2, 2007, Pages 114-120

  Atkinson, Suzanne ^a   Blanc, Ariane ^a   Lebel, Denis ^a   Bussières, Jean François ^a   Bailey, Benoit ^a   Bérard, Anick ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Cisapride; Drug interactions; Health Canada Special Access Programme; Pediatric population; Unlicensed drugs

Indexed keywords

AMITRIPTYLINE; ARYLBUTYRIC ACID DERIVATIVE; CISAPRIDE; CLARITHROMYCIN; ERYTHROMYCIN; GAMMA INTERFERON; HYDROXOCOBALAMIN; MECOBALAMIN; MELATONIN; MERCAPTAMINE; NITISINONE; STIRIPENTOL; VALPROATE SEMISODIUM;

ADOLESCENT; ADULT; ARTICLE; CANADA; CASE STUDY; CHILD; COMMUNITY CARE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG WITHDRAWAL; FEMALE; GROUPS BY AGE; HEALTH CARE ACCESS; HEALTH PROGRAM; HEART ARRHYTHMIA; HELICOBACTER INFECTION; HUMAN; INFANT; LICENSING; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PHARMACIST; QT INTERVAL; RISK ASSESSMENT; SIDE EFFECT; TEACHING HOSPITAL; TERTIARY HEALTH CARE; TREATMENT DURATION;

EID: 34548227904     PISSN: 00084123     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Special Access Programme (SAP) instructions for making a special access request. Ottawa (ON): Health Canada; [cited 2007 Mar 31]. Available from: http://www.hc-sc.gc.ca/dhpmps/acces/drugs-drogues/ index_e.html/
2. Choonara I, Conroy S. Unlicensed and off-label drug use in children: implications for safety. Drug Saf 2002;25(1):1-5.
3. Turner S, Nunn AJ, Choonara I. Unlicensed drug use in children in the UK. Paediat Perinatal Drug Ther 1997;1:52-55.
4. Health Canada. Special Access programme - drugs. Ottawa (ON): Health Canada; [cited 2005 Mar 31]. Available from: http://www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/sap_instructions_f.html
5. Règlement sur les conditions de vente des médicaments dans un établissement. D. 1694-85, 1985, G.O. 2 5650. Available from: http://www2.publicationsduquebec.gouv.qc.ca/ dynamicSearch/telecharge.php?type=3&file=/P_10/P10R6_1.HTM [cited 2005 Mar 31].
6. Halkin H, Katzir I, Kurman I, Jan J, Malkin BB. Preventing drug interactions by online prescription screening in community pharmacies and medical practices. Clin Pharmacol Ther 2001;69(4):260-265.
7. Tamblyn RM, McLeod PJ, Abrahamowicz M, Laprise R. Do too many cooks spoil the broth? Multiple physician involvement in medical management of elderly patients and potentially inappropriate drug combinations. CMAJ 1996;154(8):1177-1184.
8. Viramontes-Madrid JL, Jerjes-Sanchez C, Pelaez-Ballestas I, Aguilar-Chiu A, Hernandez-Garduno AG. [Risk of drug interactions. Combinations of drugs associated with ventricular arrhythmias]. Rev Invest Clin 2002;54(3):192-197. [Spanish].
9. Bucheler R, Schwab M, Morike K, Kalchthaler B, Mohr H, Schroder H, et al. Off label prescribing to children in primary care in Germany: retrospective cohort study. BMJ 2002; 324(7349):1311-1312.
10. Chalumeau M, Treluyer JM, Salanave B, Assathiany R, Cheron G, Crocheton N, et al. Off label and unlicensed drug use among French office based paediatricians. Arch Dis Child 2000; 83(6):502-505.
11. Conroy S. Unlicensed and off-label drug use: issues and recommendations. Paediatr Drugs 2002;4(6):353-359.
12. Conroy S, Choonara I, Impicciatore P, Mohn A, Arnell H, Rane A, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BMJ 2000;320(7227):79-82.
13. Conroy S, McIntyre J, Choonara I. Unlicensed and off label drug use in neonates. Arch Dis Child Fetal Neonatal Ed 1999;80(2):F142-F144; discussion F144-F145.
14. 'T Jong GW, Eland IA, Sturkenboom MC, van den Anker JN, Stricker BH. Unlicensed and off label prescription of drugs to children: population based cohort study. BMJ 2002;324(7349):1313-1314.
15. McIntyre J, Conroy S, Avery A, Corns H, Choonara I. Unlicensed and off label prescribing of drugs in general practice. Arch Dis Child 2000;83(6):498-501.
16. O'Donnell CP, Stone RJ, Morley CJ. Unlicensed and off-label drug use in an Australian neonatal intensive care unit. Pediatrics 2002;110(5):e52.
17. Schirm E, Tobi H, de Jong-van den Berg LT. Risk factors for unlicensed and off-label drug use in children outside the hospital. Pediatrics 2003;111(2):291-295.
18. Schirm E, Tobi H, de Jong-van den Berg LT. Unlicensed and off label drug use by children in the community: cross sectional study. BMJ 2002;324(7349):1312-1313.
19. 'T Jong GW, van der Linden PD, Bakker EM, van der Lely N, Eland IA, Stricker BH, et al. Unlicensed and off-label drug use in a paediatric ward of a general hospital in the Netherlands. Eur J Clin Pharmacol 2002;58(4):293-297.
20. 'T Jong GW, Vulto AG, de Hoog M, Schimmel KJ, Tibboel D, van den Anker JN. A survey of the use of off-label and unlicensed drugs in a Dutch children's hospital. Pediatrics 2001;108(5): 1089-1093.
21. Turner S, Gill A, Nunn T, Hewitt B, Choonara I. Use of "off-label" and unlicensed drugs in paediatric intensive care unit. Lancet 1996;347(9000):549-550.
22. Turner S, Longworth A, Nunn AJ, Choonara I. Unlicensed and off label drug use in paediatric wards: prospective study. BMJ 1998;316(7128):343-345.
23. Hansten PD, Horn JR, Hansten PD. Hansten and Horn's drug interactions analysis and management. Updated. St Louis (MO): Facts and Comparisons; 1997. Loose-leaf.
24. Drug interaction facts. Updated. St Louis (MO): JB Lippincott co, Facts and Comparisons Division; 1988.
25. Micromedex® healthcare series. Greenwood Village (CO): Thomson Healthcare Inc; 2003.
26. Jones JK, Fife D, Curkendall S, Goehring E Jr, Guo JJ, Shannon M. Coprescribing and codispensing of cisapride and contraindicated drugs. JAMA 2001;286(13):1607-1609.
27. De Bruin ML, Panneman MJ, Leufkens HG, Hoes AW, Herings RM. Use of cisapride with contraindicated drugs in the Netherlands. Ann Pharmacother 2002;36(2):338-343.
28. Règlement sur la tenue des dossiers, livres et registres par un pharmacien dans l'exercice de sa profession. R.R.Q. 1981, c. P-10, r. 19. Available from: http://www2.publicationsduquebec.gouv.qc.ca/ dynamicSearch/telecharge.php.?type=3&file=/P_10/P10R19.HTM [cited 2005 Mar 31].
29. McMullin ST, Reichley RM, Watson LA, Steib SA, Frisse ME, Bailey TC. Impact of a Web-based clinical information system on cisapride drug interactions and patient safety. Arch Intern Med 1999;159(17):2077-2082.
30. Shaoul R, Shahory R, Tamir A, Jaffe M. Comparison between pediatricians and family practitioners in the use of the prokinetic cisapride for gastroesophageal reflux disease in children. Pediatrics 2002;109(6):1118-1123.